Biolinq
PrivateLast Round
Series C
Apr 22, 2025
Est. Valuation
$405M
Total Funding Raised
$214.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Biolinq is a healthcare technology company that develops a wearable biosensor platform for continuous monitoring of metabolic health, including glucose, ketones, and lactate.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Sensors, Biotechnology
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biolinq Comparables
Compare Biolinq with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RSP Systems A/S | 84% | |
| HAGAR N.I.G. | 83% | |
| GlucoModicum | 82% |
Biolinq Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 22, 2025 | ||||
| VC Round | Apr 4, 2024 | ||||
| Series B | Nov 2, 2021 | ||||
| Series A Extension | Mar 28, 2019 | ||||
| Series A | Nov 27, 2017 |
Key People
Founding team and executive leadership
Biolinq Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Senvest Capital | Series B |
| Grey Sky Venture Partners | Series A |
| LifeSci Venture Partners | Series C, Series A, Series A Extension |
| Aphelion Capital | Series C, VC Round, Series B, Series A Extension |
| Able Partners | Series B |
| Senvest Management | VC Round, Series B |
| Longevity Vision Fund | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 28, 2026
Initial product is a Continuous Glucose Monitoring (CGM) sensor.
- Nov 1, 2025
Job posting discloses that Biolinq is a clinical stage medical device company, indicating its biosensor platform is undergoing clinical trials.
Biolinq Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Biolinq's valuation, stock price, and market status.
Is Biolinq a public or private company?
Biolinq is a private company.
What is the current stock price of Biolinq?
Biolinq is a private company with no public stock price. No recent secondary market data is available.
How much is Biolinq worth (valuation)?
Valuation information for Biolinq is not publicly available.
Can I buy Biolinq stock?
Biolinq shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Biolinq's last funding round?
Biolinq's most recent funding round was Series C on April 22, 2025.
Who are the main investors in Biolinq?
Key investors in Biolinq include LifeSci Venture Partners, Aphelion Capital, M Ventures, RiverVest Venture Partners, JDRF.
Will Biolinq IPO soon?
No public IPO plans have been announced for Biolinq.
How can I track Biolinq secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Biolinq's secondary market activity and sign up for updates.